ProMIS Neurosciences Obtains Receipt for Final Base Shelf Prospectus
08 July 2021 - 9:30PM
ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF) (the
“
Company”), a biotechnology company focused on the
discovery and development of antibody therapeutics targeting toxic
oligomers implicated in the development of neurodegenerative
diseases, is pleased to announce that it has filed, and obtained a
receipt for, a final short form base shelf prospectus (the
“
Shelf Prospectus”) with the securities regulators
in each of the provinces and territories of Canada, except Quebec.
The Shelf Prospectus allows the Company to make
offerings of common shares, warrants, units, debt securities,
subscription receipts, convertible securities or any combination
thereof for up to an aggregate total of US$50 million during the
25-month period that the Shelf Prospectus is effective. If any
securities are offered under the Shelf Prospectus, the terms of any
such securities and the intended use of the net proceeds resulting
from such offering would be described in a prospectus supplement
filed with the applicable Canadian securities regulators at the
time of such an offering.
A copy of the Shelf Prospectus can be found
under the Company’s profile on SEDAR at www.sedar.com.
The securities being referred to in this news
release have not been, nor will they be, registered under the
United States Securities Act of 1933, as amended, and may not be
offered or sold in the U.S. or to, or for the account or benefit
of, U.S. persons absent registration or an applicable exemption
from the registration requirements. This news release does not
constitute an offer to sell or the solicitation of an offer to buy
nor shall there be any sale of the securities in any jurisdiction
in which such offer, solicitation or sale would be unlawful.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development
stage biotechnology company focused on discovering and developing
antibody therapeutics selectively targeting toxic oligomers
implicated in the development and progression of neurodegenerative
diseases, in particular Alzheimer’s disease (AD), amyotrophic
lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s
proprietary target discovery engine is based on the use of two
complementary techniques. The Company applies its thermodynamic,
computational discovery platform—ProMIS™ and Collective
Coordinates—to predict novel targets, known as Disease Specific
Epitopes, on the molecular surface of misfolded proteins. Using
this unique approach, the Company is developing novel antibody
therapeutics for AD, ALS and PD. ProMIS is headquartered in
Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS
is listed on the Toronto Stock Exchange under the symbol PMN, and
on the OTCQB Venture Market under the symbol ARFXF.
For further information about ProMIS
Neurosciences, please consult the Company’s website at:
www.promisneurosciences.com
For Investor Relations please contact:Alpine
Equity AdvisorsNicholas Rigopulos,
Presidentnick@alpineequityadv.comTel. 617 901-0785
The TSX has not reviewed and does not accept
responsibility for the adequacy or accuracy of this
release.
This news release contains certain
"forward-looking statements" within the meaning of such statements
under applicable securities law. Forward-looking statements are
frequently characterized by words such as "anticipates", "plan",
"continue", "expect", "project", "intend", "believe", "anticipate",
"estimate", "may", "will", "potential", "proposed", "positioned"
and other similar words, or statements that certain events or
conditions "may" or "will" occur including but not limited to
statements related to the intent of the Company to offer and sell
any securities, the nature of any securities that may be offered
and the timing, amount and use of proceeds of any offering of
securities, and other statements related to the Company’s strategy,
projects or plans. There is no assurance that the Company will
offer, undertake or complete any sales of securities under the base
shelf prospectus or receive all necessary approvals to do so. The
reader is cautioned that forward-looking statements are based on
certain assumptions and are subject to known and unknown risks and
uncertainties (both general and specific) that contribute to the
possibility that the future events or circumstances contemplated by
the forward-looking information will not occur. Readers should also
refer to the risk factors set forth in the Company’s continuous
disclosure documents available at SEDAR (www.sedar.com). There can
be no assurance that the plans, intentions or expectations upon
which forward-looking statements are based will be realized. Actual
results may differ, and the difference may be material and adverse
to the Company and its shareholders.
ProMIS Neurosciences (TSX:PMN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ProMIS Neurosciences (TSX:PMN)
Historical Stock Chart
From Jul 2023 to Jul 2024